DS89002333 is an orally active and potent PRKACA inhibitor, with an IC 50 of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC).
Products | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PKA
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.